PsyBio Therapeutics Corp.
PSYBF · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $25 | $13 | $38 | $13 |
| Gross Profit | -$25 | -$13 | -$38 | -$13 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $152 | $3 |
| G&A Expenses | $79 | $421 | $585 | $626 |
| SG&A Expenses | $132 | $702 | $711 | $810 |
| Sales & Mktg Exp. | $53 | $281 | $126 | $184 |
| Other Operating Expenses | $0 | -$730 | $75 | $0 |
| Operating Expenses | $132 | $764 | $897 | $813 |
| Operating Income | -$157 | -$714 | -$947 | -$922 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$25 | -$10 | -$7 | $1 |
| Pre-Tax Income | -$182 | -$812 | -$942 | -$922 |
| Tax Expense | $0 | $0 | $4 | $0 |
| Net Income | -$182 | -$811 | -$942 | -$922 |
| % Margin | – | – | – | – |
| EPS | -0.001 | -0.01 | -0.015 | -0.008 |
| % Growth | 86% | 33.3% | -80.7% | – |
| EPS Diluted | -0.001 | -0.01 | -0.015 | -0.008 |
| Weighted Avg Shares Out | 128,176 | 128,176 | 62,701 | 111,339 |
| Weighted Avg Shares Out Dil | 128,176 | 128,176 | 62,701 | 111,339 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $3 | $4 | $5 |
| Depreciation & Amortization | $19 | $38 | $38 | $36 |
| EBITDA | -$163 | -$770 | -$899 | -$878 |
| % Margin | – | – | – | – |